Thirty years after the identification and cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) [1], a transformational drug therapy for most people with cystic fibrosis (CF) received regulatory approval [2,3]. Here, CFTR is linked to cystic fibrosis.